Vestmark Advisory Solutions Inc. Purchases Shares of 173,288 CRISPR Therapeutics AG (NASDAQ:CRSP)

Vestmark Advisory Solutions Inc. acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, Holdings Channel reports. The fund acquired 173,288 shares of the company’s stock, valued at approximately $10,848,000.

Other hedge funds have also modified their holdings of the company. ARK Investment Management LLC grew its holdings in shares of CRISPR Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after acquiring an additional 1,372,986 shares in the last quarter. Westfield Capital Management Co. LP acquired a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $13,506,000. Baillie Gifford & Co. raised its stake in shares of CRISPR Therapeutics by 81.1% during the 3rd quarter. Baillie Gifford & Co. now owns 441,063 shares of the company’s stock worth $20,020,000 after purchasing an additional 197,469 shares in the last quarter. Barclays PLC boosted its holdings in shares of CRISPR Therapeutics by 36.9% in the 3rd quarter. Barclays PLC now owns 510,832 shares of the company’s stock valued at $23,186,000 after buying an additional 137,629 shares during the last quarter. Finally, Armistice Capital LLC grew its stake in shares of CRISPR Therapeutics by 20.0% in the third quarter. Armistice Capital LLC now owns 600,012 shares of the company’s stock valued at $27,235,000 after buying an additional 100,012 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Stock Up 1.5 %

Shares of CRSP stock traded up $0.82 during trading hours on Friday, reaching $55.89. The company’s stock had a trading volume of 1,426,901 shares, compared to its average volume of 1,308,278. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The firm’s 50 day simple moving average is $67.75 and its 200-day simple moving average is $64.31. The company has a market capitalization of $4.74 billion, a price-to-earnings ratio of -28.52 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. The business’s revenue was up 3253.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.41) EPS. Sell-side analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the transaction, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,801 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $78.26, for a total value of $219,206.26. Following the completion of the transaction, the general counsel now directly owns 60,070 shares of the company’s stock, valued at approximately $4,701,078.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 83,992 shares of company stock valued at $6,132,335. 4.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, April 11th. Barclays boosted their price target on CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 22nd. Morgan Stanley lifted their target price on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research note on Monday, February 26th. Wells Fargo & Company increased their price target on CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Finally, Mizuho lifted their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and an average price target of $76.29.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.